Why SV2 Invested in JuneBrain
At SV2, we invest in early-stage companies that are tackling urgent social and environmental challenges with scalable, market-based solutions. We look for founders with deep founder-market fit, products that expand access for underserved communities, and business models capable of driving both impact and long-term sustainability. Just as importantly, we invest alongside our donor partners, bringing their lived experience, values, and networks into the investment process to strengthen outcomes for both communities and companies.
JuneBrain exemplifies this approach.
Rethinking Access to Brain and Eye Health
Neurological diseases affect billions of people worldwide, yet access to timely, high-quality diagnostics remains limited, especially for people with disabilities, those living in rural areas, and low-income communities. A key diagnostic tool, OCT (optical coherence tomography), has recently been added to clinical criteria for neurological diseases such as multiple sclerosis and Alzheimer’s. However, existing OCT systems are expensive, bulky, require trained technicians, and are often inaccessible to disabled patients. As a result, many patients never receive routine monitoring that could meaningfully improve care.
JuneBrain is changing that.
The company has developed a portable, accessible retinal imaging system paired with AI-driven analytics that enables fast, automated eye scans in a wide range of clinical settings. By combining hardware with software, JuneBrain allows clinicians to detect and track neurological and eye diseases more efficiently, without requiring specialized equipment or staff. This approach has the potential to bring advanced diagnostics out of specialty clinics and into neurology offices, community health centers, and other care settings where patients already are.
A Founder-Led Mission, Built Proximally
JuneBrain’s work is deeply shaped by its founder’s lived experience and clinical background. From the beginning, the company partnered formally and informally with disability advocacy organizations to inform product design, ensuring accessibility was not an afterthought, but a core requirement. This proximity to patients and providers has resulted in a solution that is both clinically rigorous and meaningfully inclusive.
The team has already demonstrated strong early validation, with clinical studies underway and growing interest from research institutions and healthcare systems. Their focus on automation and AI also aligns with a broader shift in healthcare: using intelligent software to reduce clinician burden, lower costs, and improve consistency of care.
Why JuneBrain is an SV2 Fit
As healthcare systems face persistent shortages of specialists and rising costs, access to advanced diagnostics remains limited to a small number of settings. JuneBrain’s portable, lower-cost OCT system, paired with AI-enabled software, reduces these barriers by making high-quality retinal imaging easier to deploy across neurology clinics and community care environments, supporting broader access to neurological monitoring without requiring additional specialized infrastructure.
For SV2, this combination of impact depth, clinical credibility, and commercial potential made JuneBrain a compelling investment. We’re excited to support the team as they work to make high-quality brain and eye health monitoring more accessible to all.